Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Northwest Biotherapeutics (NWBO) Return on Capital Employed (2016 - 2025)

Historic Return on Capital Employed for Northwest Biotherapeutics (NWBO) over the last 17 years, with Q3 2025 value amounting to 1.12%.

  • Northwest Biotherapeutics' Return on Capital Employed fell 9300.0% to 1.12% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.12%, marking a year-over-year decrease of 9300.0%. This contributed to the annual value of 1.62% for FY2024, which is 19300.0% down from last year.
  • According to the latest figures from Q3 2025, Northwest Biotherapeutics' Return on Capital Employed is 1.12%, which was down 9300.0% from 1.18% recorded in Q2 2025.
  • In the past 5 years, Northwest Biotherapeutics' Return on Capital Employed ranged from a high of 6.51% in Q2 2023 and a low of 0.23% during Q3 2021
  • Over the past 5 years, Northwest Biotherapeutics' median Return on Capital Employed value was 1.18% (recorded in 2025), while the average stood at 1.74%.
  • In the last 5 years, Northwest Biotherapeutics' Return on Capital Employed skyrocketed by 57300bps in 2023 and then crashed by -42700bps in 2024.
  • Northwest Biotherapeutics' Return on Capital Employed (Quarter) stood at 0.53% in 2021, then surged by 34bps to 0.71% in 2022, then skyrocketed by 404bps to 3.58% in 2023, then tumbled by -54bps to 1.65% in 2024, then tumbled by -32bps to 1.12% in 2025.
  • Its Return on Capital Employed was 1.12% in Q3 2025, compared to 1.18% in Q2 2025 and 1.22% in Q1 2025.